GUT-PD: Constipation and Changes in the Gut Flora in Parkinson's Disease: a Pilot Study
Study Details
Study Description
Brief Summary
The aim of this study is to investigate the link between gut health and Parkinson's disease
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Parkinson's disease (PD) is a common, age-related neurological condition, affecting approximately 145,000 people in the United Kingdom. Diagnostic symptoms include stiffness, tremor, unsteadiness and slow movements. Interestingly, while PD is usually considered to be a neurological condition, pathological changes occur in the gut years before diagnosis, often causing constipation. As such, the gut has attracted attention as a possible therapeutic target.
Previous studies have shown different profiles of gut bacteria and the short chain fatty acids (SCFAs) they produce in people with PD. There is evidence these changes might be significant to the disease course, as faecal transplants from people with PD worsened symptoms in a mouse model of PD. The mechanism for this is unclear, but changes in SCFAs and gut wall inflammation, have both been suggested. Studies so far have compared gut bacteria in people with and without PD, however, as the healthy controls often don't have constipation, it is unclear if the differences seen are due to PD itself or the associated constipation.
This pilot study aims to determine differences in the frequency of gut micro-organisms (bacteria, fungi and archaea) and gut function, other than those caused by constipation. 40 participants with a new diagnosis of PD will be recruited from Movement Disorder clinics within National Health Service (NHS) Grampian. 40 healthy (non-PD) controls will be recruited from the PD participants households (whenever feasible). All 80 participants will be clinically assessed and asked to provide two stool samples. The samples will be analysed for the frequency of gut micro-organisms, changes in gut function (short chain fatty acid concentrations) and gut inflammation (calprotectin concentrations).
The aim of this pilot study is to determine the key differences in gut micro-organisms in PD compared to controls, which may have a role in disease progression. It is likely that the results of this proof of concept study would need to be confirmed in a larger study before the investigators are able to plan an intervention trial, such as testing a prebiotic product, with the aim of normalising gut micro-organisms, and potentially modifying the disease course.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Parkinson disease Participants with newly diagnosed Parkinson's disease |
|
| Control Subjects Control subjects - will be selected from household/spousal contacts of the participants with Parkinson's disease |
Outcome Measures
Primary Outcome Measures
- Micro-organism prevalence in stool sample [Baseline]
Stool samples will be posted to the Rowett Institute, and processed and analysed in the laboratory at The Rowett Institute, University of Aberdeen. The samples will be analysed for water content and microbial RNA/DNA will be extracted for genome analysis. When the analysis is complete, the faecal samples will be destroyed.
- Micro-organism prevalence in stool sample [Within two months of baseline]
Stool samples will be posted to the Rowett Institute, and processed and analysed in the laboratory at The Rowett Institute, University of Aberdeen. The samples will be analysed for water content and microbial RNA/DNA will be extracted for genome analysis. When the analysis is complete, the faecal samples will be destroyed.
Secondary Outcome Measures
- Analysis of stool samples for concentration of short chain fatty acids [Baseline]
Stool samples will be posted to the Rowett Institute via Royal Mail. Samples will be processed and analysed in the laboratory at The Rowett Institute, University of Aberdeen. The samples will be analysed for short chain fatty acid concentration (µmol/g).
- Analysis of stool samples for concentration of calprotectin [Baseline]
Stool samples will be posted to the Rowett Institute via Royal Mail. Samples will be processed and analysed in the laboratory at The Rowett Institute, University of Aberdeen. The samples will be analysed for short calprotectin concentration (µg/g).
- Analysis of stool samples for markers of gut function (short chain fatty acids and calprotectin) [Within two months of the baseline sample]
Stool samples will be posted to the Rowett Institute via Royal Mail. Samples will be processed and analysed in the laboratory at The Rowett Institute, University of Aberdeen. The samples will be analysed for short chain fatty acid (SCFA) profile and calprotectin concentration. When the analysis is complete, the faecal samples will be destroyed.
- To assess the extent of swallowing problems (dysphagia) by a questionnaire [Baseline]
Participants will be asked to completed a standardized swallowing questionnaire (Swallowing Disturbance Questionnaire), which has been validated in people with Parkinson's disease. The score ranges from 0-43, with a higher score increasing the likelihood for a swallowing problem, which would require further investigation
- To assess the extent of swallowing problems using a standardized swallowing test [Baseline]
Participants will be asked to drink 150 millilitres of cold water from a clear cup. The rater will sit at their side and record them on video for later analysis. The speed in ml/second and volume per average swallow will be recorded by determining if any residual volume is left, the number of seconds to complete the task and the number of swallows. The test will be terminated if there is any indication of aspiration of liquid.
- To assess the extent of swallowing problems using a standardized swallowing test [Four weeks after the baseline assessment]
Participants will be asked to drink 150 millilitres of cold water from a clear cup. The rater will sit at their side and record them on video for later analysis. The speed in ml/second and volume per average swallow will be recorded by determining if any residual volume is left, the number of seconds to complete the task and the number of swallows. The test will be terminated if there is any indication of aspiration of liquid.
- To assess taste sensation using a simple test [Baseline]
Participants taste recognition will be assessed using standardized taste strips from Burghart (sweet, salty, sour and bitter)
- To assess dietary intake over a 24 hour period using a structured interview [Baseline]
Following the initial visit, the participant will receive a phone call from a trained member of the team to perform a 24-hour dietary recall interview. This is a structured interview where participants are asked to recall all food and beverage consumption over a 24-hour period and further questions are asked to determine further details, including portion size and ingredients and cooking methods used. The whole interview usually takes 20 to 60 minutes.
- To assess the reliability of bio-impedence analysis in determining fat mass in older adults with and without PD [Baseline]
Fat mass in kilograms will be measured using a seca mBCA 525 bio-impedence machine.
- To assess the reliability of bio-impedence analysis in determining fat mass in older adults [Four weeks after baseline assessment]
Fat mass in kilograms will be measured using a seca mBCA 525 bio-impedence machine.
- To assess the reliability of bio-impedence analysis in determining fat mass in older adults [Baseline]
Fat free mass in kilograms will be measured using a seca mBCA 525 bio-impedence machine.
- To assess the reliability of bio-impedence analysis in determining fat mass in older adults [Four weeks after the baseline assessment]
Fat free mass in kilograms will be measured using a seca mBCA 525 bio-impedence machine.
Eligibility Criteria
Criteria
Inclusion Criteria:
Participants with Parkinson's disease •Community-dwelling patients with newly diagnosed PD who have not yet started medication for Parkinson's disease.
Control Participants
•Healthy (non-Parkinsonian) members of the participants household will be invited to act as controls.
Exclusion Criteria:
-
Use of oral or intravenous antibiotics in the last 8 weeks.
-
Active gastrointestinal disease, not including constipation or irritable bowel syndrome without other symptoms.
-
Current use of medications which cause/worsen constipation e.g., opioids, tramadol, gabapentin, pregabalin.
-
Potential controls will be excluded if they report prodromal symptoms of PD, such as anosmia or rapid eye movement (REM) sleep disorder or display parkinsonian signs on examination.
-
Inability to give informed consent at any stage of the study e.g., because of dementia.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Human Nutrition Unit, Rowett Institute, University of Aberdeen | Aberdeen | Aberdeen City | United Kingdom | AB25 2ZD |
Sponsors and Collaborators
- University of Aberdeen
- Biomathematics & Statistics Scotland (BioSS)
- NHS Grampian
Investigators
- Principal Investigator: Isobel JM Sleeman, BMBCh, PhD, University of Aberdeen
Study Documents (Full-Text)
None provided.More Information
Publications
- De Pablo-Fernandez E, Gebeyehu GG, Flain L, Slater R, Frau A, Ijaz UZ, Warner T, Probert C. The faecal metabolome and mycobiome in Parkinson's disease. Parkinsonism Relat Disord. 2022 Feb;95:65-69. doi: 10.1016/j.parkreldis.2022.01.005. Epub 2022 Jan 13.
- Gage H, Kaye J, Kimber A, Storey L, Egan M, Qiao Y, Trend P. Correlates of constipation in people with Parkinson's. Parkinsonism Relat Disord. 2011 Feb;17(2):106-11. doi: 10.1016/j.parkreldis.2010.11.003. Epub 2010 Dec 3.
- Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C. Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol. 2014 Feb;127(2):235-41. doi: 10.1007/s00401-013-1214-6. Epub 2013 Nov 17.
- Jaffrin MY, Morel H. Body fluid volumes measurements by impedance: A review of bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) methods. Med Eng Phys. 2008 Dec;30(10):1257-69. doi: 10.1016/j.medengphy.2008.06.009. Epub 2008 Aug 3.
- Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Mov Disord. 2007 Oct 15;22(13):1917-21. doi: 10.1002/mds.21625.
- Mueller C, Kallert S, Renner B, Stiassny K, Temmel AF, Hummel T, Kobal G. Quantitative assessment of gustatory function in a clinical context using impregnated "taste strips". Rhinology. 2003 Mar;41(1):2-6.
- Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016 Dec 1;167(6):1469-1480.e12. doi: 10.1016/j.cell.2016.11.018.
- Schwiertz A, Spiegel J, Dillmann U, Grundmann D, Burmann J, Fassbender K, Schafer KH, Unger MM. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease. Parkinsonism Relat Disord. 2018 May;50:104-107. doi: 10.1016/j.parkreldis.2018.02.022. Epub 2018 Feb 12.
- Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Burmann J, Fassbender K, Schwiertz A, Schafer KH. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord. 2016 Nov;32:66-72. doi: 10.1016/j.parkreldis.2016.08.019. Epub 2016 Aug 26.
- 2-048-21